Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Prajmalium→

Prajmalium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
35080-11-6
Molecular formula
C23H33N2O2+
Molecular weight
369.5 g/mol
Drug class
Class Ia antiarrhythmiccardiac fast sodium-channel blocker
Mechanism of action
Blocks fast voltage-gated sodium channels in cardiac myocytes, slowing phase-0 depolarisation and conduction velocity. Class Ia activity also prolongs action-potential duration and effective refractory period through effects on repolarising potassium currents.
Indications / reported uses
  • Historically used for treatment of selected supraventricular and ventricular arrhythmias in countries where prajmalium remains authorised; availability and clinical role are jurisdiction-specific.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=prajmalium · https://www.ncbi.nlm.nih.gov/mesh/?term=prajmalium · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Prajmalium Environmental Risk Assessment (ERA) (the Prajmalium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.